Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Medicale (MCLE) EBITDA (2020 - 2025)

Medicale (MCLE) has disclosed EBITDA for 6 consecutive years, with -$8654.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 44.2% year-over-year to -$8654.0, compared with a TTM value of -$33493.0 through Sep 2025, up 38.78%, and an annual FY2025 reading of -$33493.0, up 38.78% over the prior year.
  • EBITDA was -$8654.0 for Q3 2025 at Medicale, down from -$3575.0 in the prior quarter.
  • Across five years, EBITDA topped out at -$3575.0 in Q2 2025 and bottomed at -$19307.0 in Q4 2023.
  • Average EBITDA over 5 years is -$10055.3, with a median of -$8654.0 recorded in 2025.
  • The sharpest move saw EBITDA crashed 121.56% in 2023, then surged 61.51% in 2025.
  • Year by year, EBITDA stood at -$18096.0 in 2021, then skyrocketed by 51.85% to -$8714.0 in 2022, then crashed by 121.56% to -$19307.0 in 2023, then rose by 22.33% to -$14995.0 in 2024, then soared by 42.29% to -$8654.0 in 2025.
  • Business Quant data shows EBITDA for MCLE at -$8654.0 in Q3 2025, -$3575.0 in Q2 2025, and -$6269.0 in Q1 2025.